Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Symptomatic and Neurotrophic Efficacy of a5-Gamma-Aminobutyric Acid-A Positive Allosteric Modulation

FY 2024-25

Summary
Alzheimer Disease (AD) is a chronic and debilitating neurodegenerative disorder, affecting over 55 million people worldwide. Progressive symptoms include cognitive decline, amyloid and tau load, and loss of neurological function, ultimately leading to patient death. Despite persistent efforts by the scientific community, effective medications that can improve patient life quality are lacking. This gap in treatment options calls for finding a new target for improving cognitive symptoms and brain pathology in the AD population. The a5-Gamma-Aminobutyric Acid-A receptor ( a5-GABAAR) is a part of an important inhibitory signaling pathway in the brain, implicated in age-related cognitive decline. Our research team developed a novel molecule that is a a5-GABAAR positive allosteric modulator. It selectively increases the a5-GABAARs activity, and reverses cognitive deficits and neuronal shrinkage brought by aging and amyloid load. However, it is still unclear if this drug specifically acts on a5-GABAARs to produce these beneficial effects, or if there are other mechanisms at play. To answer this question, my study uses transgenic mice that have a point mutation at their a5-GABAARs allosteric binding site ( a5KI), which makes them insensitive to our novel molecule. Two groups of AD mouse models will be used: those that have mutated a5-GABAARs, and those that do not. I hypothesize that, following chronic treatment of our novel molecule, the drug-sensitive group of mice will show better cognitive performance and more complex neuronal morphology than the drug-insensitive strain, despite both groups having amyloid pathology. Conclusively, my work will be able to confirm a5-GABAAR positive allosteric modulation as a promising new target for managing Alzheimer Disease progression.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530232
Name
Chen Jingxin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Symptomatic and Neurotrophic Efficacy of a5-Gamma-Aminobutyric Acid-A Positive Allosteric Modulation
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Alzheimer'S Disease; Amyloid Plaques; Behavioural Assays; Cognitive Dysfunction; Gamma-Aminobutyric Acid; Neuronal Atrophy; Positive Allosteric Modulator; Preclinical; Spine Density
Abstract
Alzheimer Disease (AD) is a chronic and debilitating neurodegenerative disorder, affecting over 55 million people worldwide. Progressive symptoms include cognitive decline, amyloid and tau load, and loss of neurological function, ultimately leading to patient death. Despite persistent efforts by the scientific community, effective medications that can improve patient life quality are lacking. This gap in treatment options calls for finding a new target for improving cognitive symptoms and brain pathology in the AD population. The a5-Gamma-Aminobutyric Acid-A receptor ( a5-GABAAR) is a part of an important inhibitory signaling pathway in the brain, implicated in age-related cognitive decline. Our research team developed a novel molecule that is a a5-GABAAR positive allosteric modulator. It selectively increases the a5-GABAARs activity, and reverses cognitive deficits and neuronal shrinkage brought by aging and amyloid load. However, it is still unclear if this drug specifically acts on a5-GABAARs to produce these beneficial effects, or if there are other mechanisms at play. To answer this question, my study uses transgenic mice that have a point mutation at their a5-GABAARs allosteric binding site ( a5KI), which makes them insensitive to our novel molecule. Two groups of AD mouse models will be used: those that have mutated a5-GABAARs, and those that do not. I hypothesize that, following chronic treatment of our novel molecule, the drug-sensitive group of mice will show better cognitive performance and more complex neuronal morphology than the drug-insensitive strain, despite both groups having amyloid pathology. Conclusively, my work will be able to confirm a5-GABAAR positive allosteric modulation as a promising new target for managing Alzheimer Disease progression.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen, Jingxin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~